(Reuters) -Boston Scientific raised its annual profit forecast on Wednesday, after the medical device maker beat third-quarter profit estimates on strong demand for its heart devices.

The company, which generates most of its revenue from heart devices such as pacemakers and stents, has benefited from rising demand for surgical procedures, helping offset broader concerns over healthcare spending.

Larger rival Johnson & Johnson last week also reported a 6.8% rise in quarterly medical devices sales.

Boston Scientific, last week, said it will buy the remaining equity in privately held Nalu Medical for about $533 million in cash, expanding its portfolio of treatments for chronic pain.

Boston Scientific, which also makes equipment for gastrointestinal and pulmonary treatments, expects 2025 a

See Full Page